ArticleJournal of registry management2025
Burden of HIV among Patients Undergoing Cancer Treatment: Analysis of Population Cancer Registry in Northern Tanzania.
Article in Journal of registry management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: The burden of cancer in sub-Saharan African countries is escalating with a rising Human Immunodeficiency Virus (HIV) prevalence. However, information about the burden of HIV on cancer epidemiology is scarce. Specifically, little is known about HIV infection among the cancer cases registered in the Kilimanjaro Population Cancer Registry (KCR) despite the presence of this infection in Tanzania. Thus, our study aimed to assess the burden of HIV in cancer patients by evaluating HIV serostatus information among recorded cases of malignancies in the KCR. Methods: This secondary data analysis examined records of all cancer cases registered in the KCR from January 2018 through December 2022 to assess the status of HIV infection among the cancer cases. Variables assessed were demographic information, type of cancer, and HIV serostatus. Proportions were analyzed using descriptive data. Results: A total of 5,508 cancer cases were recorded from 2018 through 2022. HIV serostatus was documented in 4.8% (226/5,508) of the cancer cases, 68% of which were HIV seropositive with a slight female predominance (male-to-female ratio of 1:1.7). Cervical cancer was the leading malignancy (18%) with recorded HIV serostatus. Patients aged 18-50 years and females had the highest prevalence of HIV infection (64.6% and 63.5%). Conclusion: HIV infection is still underreported among cancer patients in the cancer registry of the Kilimanjaro region with only 4.8% of malignancies registered in KCR having a documented HIV serostatus. HIV serostatus was mostly documented in AIDS-defining cancers. Thus, efforts to support HIV counseling and testing among cancer patients should be made, as this will also affect treatment plans and monitoring.
Indexed as
Identifiers
41281964PMC12636237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.